10 research outputs found
Injection seeded, diode pumped regenerative ring Nd:YAG amplifier for spaceborne laser ranging technology development
A small, all solid state, regenerative ring amplifier designed as a prototype for space application is discussed. Novel features include dual side pumping of the Nd:YAG crystal and a triangular ring cavity design which minimizes the number of optical components and losses. The amplifier is relatively small (3 ns round trip time) even though standard optical elements are employed. The ring regeneratively amplifies a 100 ps single pulse by approximately 10(exp 5) at a repetition rate of 10 to 100 Hz. The amplifier is designed to be injection seeded with a pulsed, 100 ps laser diode at 1.06 microns, but another Nd:YAG laser system supplying higher pulse energies was employed for laboratory experiment. This system is a prototype laser oscillator for the Geoscience Laser Ranging System (GLRS) platform. Results on measurements of beam quality, astigmatism, and gain are given
Genomic–transcriptomic evolution in lung cancer and metastasis
Intratumour heterogeneity (ITH) fuels lung cancer evolution, which leads to immune evasion and resistance to therapy. Here, using paired whole-exome and RNA sequencing data, we investigate intratumour transcriptomic diversity in 354 non-small cell lung cancer tumours from 347 out of the first 421 patients prospectively recruited into the TRACERx study. Analyses of 947 tumour regions, representing both primary and metastatic disease, alongside 96 tumour-adjacent normal tissue samples implicate the transcriptome as a major source of phenotypic variation. Gene expression levels and ITH relate to patterns of positive and negative selection during tumour evolution. We observe frequent copy number-independent allele-specific expression that is linked to epigenomic dysfunction. Allele-specific expression can also result in genomic–transcriptomic parallel evolution, which converges on cancer gene disruption. We extract signatures of RNA single-base substitutions and link their aetiology to the activity of the RNA-editing enzymes ADAR and APOBEC3A, thereby revealing otherwise undetected ongoing APOBEC activity in tumours. Characterizing the transcriptomes of primary–metastatic tumour pairs, we combine multiple machine-learning approaches that leverage genomic and transcriptomic variables to link metastasis-seeding potential to the evolutionary context of mutations and increased proliferation within primary tumour regions. These results highlight the interplay between the genome and transcriptome in influencing ITH, lung cancer evolution and metastasis
Compact, Passively Q-Switched Nd:YAG Laser for the MESSENGER Mission to the Planet Mercury
A compact, passively Q-switched Nd:YAG laser has been developed for the Mercury Laser Altimeter (MLA) instrument which is an instrument on the MESSENGER mission to the planet Mercury. The laser achieves 5.4 percent efficiency with a near diffraction limited beam. It has passed all space flight environmental tests at system, instrument, and satellite integration. The laser design draws on a heritage of previous laser altimetry missions, specifically ISESAT and Mars Global Surveyor; but incorporates thermal management features unique to the requirements of an orbit of the planet Mercury
Facile Electron Transfer during Formation of Cluster X and Kinetic Competence of X for Tyrosyl Radical Production in Protein R2 of Ribonucleotide Reductase from Mouse â€
Reducing bias in bacterial community analysis of lower respiratory infections
High-throughput pyrosequencing and quantitative PCR (Q-PCR) analysis offer greatly improved
accuracy and depth of characterisation of lower respiratory infections. However, such approaches
suffer from an inability to distinguish between DNA derived from viable and non-viable bacteria. This
discrimination represents an important step in characterising microbial communities, particularly in
contexts with poor clearance of material or high antimicrobial stress, as non-viable bacteria and
extracellular DNA can contribute significantly to analyses. Pre-treatment of samples with propidium
monoazide (PMA) is an effective approach to non-viable cell exclusion (NVCE). However, the impact
of NVCE on microbial community characteristics (abundance, diversity, composition and structure)
is not known. Here, adult cystic fibrosis (CF) sputum samples were used as a paradigm. The effects
of PMA treatment on CF sputum bacterial community characteristics, as analysed by pyrosequencing
and enumeration by species-specific (Pseudomonas aeruginosa) and total bacterial Q-PCR,
were assessed. At the local community level, abundances of both total bacteria and of P. aeruginosa
were significantly lower in PMA-treated sample portions. Meta-analysis indicated no overall
significant differences in diversity; however, PMA treatment resulted in a significant alteration in
local community membership in all cases. In contrast, at the metacommunity level, PMA treatment
resulted in an increase in community evenness, driven by an increase in diversity, predominately
representing rare community members. Importantly, PMA treatment facilitated the detection of both
recognised and emerging CF pathogens, significantly influencing ‘core’ and ‘satellite’ taxa group
membership. Our findings suggest failure to implement NVCE may result in skewed bacterial
community analyses
Elevated cytokine and chemokine levels in the placenta are associated with in-utero HIV-1 mother-to-child transmission
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy. RESULTS: In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular disease) were followed for a median of 3.2 years (interquartile range, 2.2 to 4.4). A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P=0.06 for superiority). The rates of death from cardiovascular causes, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary syndrome, and the incidence of acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the two groups. CONCLUSIONS: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo